| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DNA Repair | 10 | 2016 | 127 | 2.260 |
Why?
|
| Cell Cycle Proteins | 7 | 2023 | 230 | 2.000 |
Why?
|
| Proto-Oncogene Proteins | 6 | 2021 | 411 | 1.770 |
Why?
|
| DNA Damage | 10 | 2017 | 190 | 1.390 |
Why?
|
| Thymidylate Synthase | 6 | 2011 | 42 | 1.360 |
Why?
|
| Antineoplastic Agents | 8 | 2021 | 1070 | 1.230 |
Why?
|
| Uracil | 4 | 2012 | 18 | 1.000 |
Why?
|
| Thioguanine | 2 | 2017 | 4 | 0.990 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2023 | 331 | 0.950 |
Why?
|
| DNA-Binding Proteins | 5 | 2017 | 700 | 0.860 |
Why?
|
| DNA Methylation | 3 | 2016 | 193 | 0.850 |
Why?
|
| DNA | 7 | 2013 | 597 | 0.830 |
Why?
|
| Neoplasms | 8 | 2023 | 1664 | 0.820 |
Why?
|
| Uracil-DNA Glycosidase | 3 | 2012 | 17 | 0.800 |
Why?
|
| Cell Survival | 7 | 2021 | 901 | 0.800 |
Why?
|
| Benzoic Acid | 1 | 2021 | 5 | 0.790 |
Why?
|
| DNA Glycosylases | 4 | 2013 | 21 | 0.780 |
Why?
|
| Recombination, Genetic | 3 | 2011 | 62 | 0.770 |
Why?
|
| Small Molecule Libraries | 1 | 2021 | 53 | 0.750 |
Why?
|
| Biological Therapy | 1 | 2020 | 8 | 0.710 |
Why?
|
| Mitosis | 2 | 2017 | 76 | 0.690 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 100 | 0.650 |
Why?
|
| Gold | 3 | 2010 | 76 | 0.640 |
Why?
|
| Bacteria | 1 | 2020 | 193 | 0.630 |
Why?
|
| Fluorouracil | 3 | 2014 | 130 | 0.610 |
Why?
|
| Homologous Recombination | 1 | 2017 | 13 | 0.610 |
Why?
|
| Peptides | 3 | 2020 | 455 | 0.580 |
Why?
|
| Rad51 Recombinase | 3 | 2011 | 16 | 0.580 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2016 | 21 | 0.570 |
Why?
|
| Capsid Proteins | 1 | 2016 | 27 | 0.560 |
Why?
|
| Cervix Uteri | 1 | 2016 | 64 | 0.560 |
Why?
|
| DNA, Viral | 1 | 2016 | 114 | 0.550 |
Why?
|
| Quinazolines | 5 | 2008 | 70 | 0.530 |
Why?
|
| Thiophenes | 5 | 2008 | 76 | 0.530 |
Why?
|
| Epithelial Cells | 2 | 2016 | 431 | 0.490 |
Why?
|
| Biomedical Research | 1 | 2018 | 310 | 0.480 |
Why?
|
| HeLa Cells | 4 | 2021 | 237 | 0.470 |
Why?
|
| Cell Line | 7 | 2017 | 1752 | 0.430 |
Why?
|
| Nanotubes | 2 | 2010 | 22 | 0.420 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2012 | 57 | 0.420 |
Why?
|
| Recombinational DNA Repair | 1 | 2011 | 6 | 0.410 |
Why?
|
| DNA Replication | 1 | 2012 | 167 | 0.400 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2021 | 1745 | 0.400 |
Why?
|
| DEAD-box RNA Helicases | 3 | 2020 | 20 | 0.400 |
Why?
|
| Structure-Activity Relationship | 5 | 2021 | 420 | 0.400 |
Why?
|
| DNA Mismatch Repair | 1 | 2011 | 42 | 0.380 |
Why?
|
| Animals | 18 | 2022 | 20880 | 0.370 |
Why?
|
| Humans | 34 | 2023 | 68549 | 0.370 |
Why?
|
| Azepines | 2 | 2020 | 15 | 0.360 |
Why?
|
| Guanine | 3 | 2010 | 21 | 0.360 |
Why?
|
| Apoptosis | 6 | 2016 | 1641 | 0.350 |
Why?
|
| Reactive Nitrogen Species | 1 | 2009 | 32 | 0.350 |
Why?
|
| Quinacrine | 3 | 2016 | 10 | 0.340 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2011 | 332 | 0.340 |
Why?
|
| Imidazoles | 2 | 2020 | 175 | 0.340 |
Why?
|
| Phenotype | 1 | 2012 | 946 | 0.340 |
Why?
|
| Metal Nanoparticles | 3 | 2010 | 88 | 0.330 |
Why?
|
| Protein Kinases | 3 | 2016 | 122 | 0.330 |
Why?
|
| Thymidine Monophosphate | 1 | 2008 | 5 | 0.330 |
Why?
|
| Microglia | 2 | 2019 | 143 | 0.320 |
Why?
|
| Drug Approval | 2 | 2020 | 50 | 0.300 |
Why?
|
| Biosimilar Pharmaceuticals | 2 | 2020 | 25 | 0.300 |
Why?
|
| Histones | 2 | 2022 | 111 | 0.300 |
Why?
|
| Molecular Structure | 4 | 2021 | 397 | 0.290 |
Why?
|
| DNA Breaks | 1 | 2006 | 2 | 0.290 |
Why?
|
| Drug Design | 3 | 2023 | 107 | 0.280 |
Why?
|
| Sister Chromatid Exchange | 1 | 2005 | 7 | 0.270 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2014 | 77 | 0.270 |
Why?
|
| Substrate Specificity | 2 | 2008 | 234 | 0.260 |
Why?
|
| Adenine | 1 | 2005 | 46 | 0.250 |
Why?
|
| Chromosomal Instability | 2 | 2017 | 14 | 0.250 |
Why?
|
| Checkpoint Kinase 1 | 3 | 2016 | 6 | 0.250 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2021 | 111 | 0.240 |
Why?
|
| Mice | 9 | 2019 | 8474 | 0.240 |
Why?
|
| Cell Line, Tumor | 7 | 2020 | 1851 | 0.240 |
Why?
|
| Nanotechnology | 1 | 2005 | 109 | 0.240 |
Why?
|
| Phosphorylation | 3 | 2012 | 1200 | 0.230 |
Why?
|
| Adenomatous Polyposis Coli Protein | 2 | 2014 | 14 | 0.230 |
Why?
|
| DNA Polymerase beta | 4 | 2009 | 9 | 0.230 |
Why?
|
| Cell Proliferation | 4 | 2021 | 1174 | 0.220 |
Why?
|
| Protein Binding | 6 | 2020 | 1027 | 0.220 |
Why?
|
| Tyrosine-tRNA Ligase | 1 | 2022 | 2 | 0.210 |
Why?
|
| HT29 Cells | 3 | 2011 | 42 | 0.210 |
Why?
|
| Cell Cycle | 5 | 2014 | 312 | 0.200 |
Why?
|
| RNA, Small Interfering | 3 | 2020 | 434 | 0.190 |
Why?
|
| Cytoplasmic Granules | 1 | 2020 | 19 | 0.190 |
Why?
|
| Replication Protein A | 2 | 2011 | 9 | 0.180 |
Why?
|
| Peptidomimetics | 1 | 2020 | 7 | 0.180 |
Why?
|
| Adenosine Triphosphate | 1 | 2021 | 314 | 0.180 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 66 | 0.180 |
Why?
|
| Hematinics | 1 | 2020 | 52 | 0.180 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 131 | 0.180 |
Why?
|
| Molecular Docking Simulation | 3 | 2020 | 78 | 0.180 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 1 | 2019 | 13 | 0.180 |
Why?
|
| Breast Neoplasms | 3 | 2016 | 1533 | 0.170 |
Why?
|
| Colonic Neoplasms | 2 | 2014 | 299 | 0.170 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2020 | 194 | 0.160 |
Why?
|
| Folic Acid Antagonists | 2 | 2008 | 20 | 0.160 |
Why?
|
| Telomere | 1 | 2017 | 59 | 0.150 |
Why?
|
| Polymerase Chain Reaction | 2 | 2016 | 492 | 0.150 |
Why?
|
| Dietary Supplements | 1 | 2020 | 331 | 0.150 |
Why?
|
| DNA Repair Enzymes | 1 | 2016 | 53 | 0.140 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2019 | 435 | 0.140 |
Why?
|
| Methyl Methanesulfonate | 2 | 2006 | 7 | 0.140 |
Why?
|
| Nucleus Accumbens | 1 | 2019 | 417 | 0.130 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 208 | 0.130 |
Why?
|
| Gene Knockdown Techniques | 2 | 2014 | 196 | 0.130 |
Why?
|
| Etoposide | 2 | 2012 | 64 | 0.130 |
Why?
|
| DNA Breaks, Double-Stranded | 2 | 2012 | 24 | 0.130 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2012 | 88 | 0.120 |
Why?
|
| Cyclins | 1 | 2014 | 50 | 0.120 |
Why?
|
| Anticarcinogenic Agents | 2 | 2012 | 52 | 0.120 |
Why?
|
| Cocaine | 1 | 2019 | 555 | 0.120 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2014 | 60 | 0.120 |
Why?
|
| Students | 1 | 2016 | 233 | 0.120 |
Why?
|
| G2 Phase | 2 | 2011 | 26 | 0.120 |
Why?
|
| Fibroblasts | 3 | 2010 | 902 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 627 | 0.110 |
Why?
|
| 5-Methylcytosine | 1 | 2013 | 3 | 0.110 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1054 | 0.110 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2012 | 2 | 0.110 |
Why?
|
| S Phase | 1 | 2012 | 38 | 0.110 |
Why?
|
| Methylation | 1 | 2013 | 56 | 0.110 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2012 | 37 | 0.110 |
Why?
|
| Purines | 1 | 2013 | 39 | 0.110 |
Why?
|
| cdc25 Phosphatases | 1 | 2012 | 2 | 0.110 |
Why?
|
| Carotenoids | 1 | 2012 | 45 | 0.110 |
Why?
|
| Wnt Proteins | 1 | 2012 | 57 | 0.110 |
Why?
|
| Intracellular Space | 1 | 2012 | 42 | 0.110 |
Why?
|
| Protein Structure, Tertiary | 3 | 2021 | 322 | 0.110 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2011 | 5 | 0.100 |
Why?
|
| Ligands | 2 | 2021 | 317 | 0.100 |
Why?
|
| DNA Topoisomerases | 1 | 2011 | 1 | 0.100 |
Why?
|
| Topoisomerase Inhibitors | 1 | 2011 | 4 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2013 | 178 | 0.100 |
Why?
|
| Protein Transport | 1 | 2012 | 280 | 0.100 |
Why?
|
| Validation Studies as Topic | 1 | 2011 | 7 | 0.100 |
Why?
|
| Flow Cytometry | 2 | 2012 | 489 | 0.100 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 163 | 0.100 |
Why?
|
| Giant Cells | 1 | 2011 | 14 | 0.100 |
Why?
|
| Methylnitronitrosoguanidine | 2 | 2010 | 8 | 0.100 |
Why?
|
| Nucleotides | 2 | 2008 | 29 | 0.100 |
Why?
|
| Genetic Vectors | 1 | 2011 | 311 | 0.090 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2009 | 7 | 0.090 |
Why?
|
| Time Factors | 4 | 2005 | 4655 | 0.090 |
Why?
|
| Intestinal Neoplasms | 1 | 2009 | 30 | 0.090 |
Why?
|
| South Carolina | 1 | 2016 | 2752 | 0.090 |
Why?
|
| Blotting, Western | 2 | 2012 | 954 | 0.090 |
Why?
|
| Catalytic Domain | 1 | 2009 | 99 | 0.090 |
Why?
|
| Embryo, Mammalian | 2 | 2010 | 176 | 0.080 |
Why?
|
| Metabolic Clearance Rate | 1 | 2009 | 48 | 0.080 |
Why?
|
| Drug Delivery Systems | 1 | 2011 | 236 | 0.080 |
Why?
|
| Models, Molecular | 2 | 2014 | 546 | 0.080 |
Why?
|
| Prospective Studies | 1 | 2016 | 3703 | 0.080 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2010 | 214 | 0.080 |
Why?
|
| Protein Conformation | 1 | 2009 | 362 | 0.080 |
Why?
|
| Magnetics | 1 | 2008 | 52 | 0.080 |
Why?
|
| Adenoma | 1 | 2009 | 132 | 0.080 |
Why?
|
| Particle Size | 1 | 2009 | 201 | 0.080 |
Why?
|
| Chromosomes, Human | 1 | 2008 | 14 | 0.080 |
Why?
|
| Folic Acid Deficiency | 1 | 2008 | 16 | 0.080 |
Why?
|
| DNA, Neoplasm | 1 | 2008 | 95 | 0.080 |
Why?
|
| Cell Differentiation | 1 | 2013 | 1034 | 0.080 |
Why?
|
| Silicon Dioxide | 1 | 2008 | 61 | 0.080 |
Why?
|
| Nuclear Proteins | 1 | 2010 | 271 | 0.080 |
Why?
|
| Signal Transduction | 2 | 2019 | 2689 | 0.080 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 659 | 0.080 |
Why?
|
| Capecitabine | 1 | 2007 | 11 | 0.080 |
Why?
|
| Surface Properties | 1 | 2009 | 363 | 0.080 |
Why?
|
| Folic Acid | 1 | 2008 | 121 | 0.080 |
Why?
|
| Materials Testing | 1 | 2009 | 263 | 0.080 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2009 | 284 | 0.070 |
Why?
|
| Cells, Cultured | 2 | 2019 | 2673 | 0.070 |
Why?
|
| Deoxycytidine | 1 | 2007 | 83 | 0.070 |
Why?
|
| DNA Primers | 1 | 2007 | 302 | 0.070 |
Why?
|
| Green Fluorescent Proteins | 1 | 2007 | 200 | 0.070 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 1033 | 0.070 |
Why?
|
| Mass Spectrometry | 1 | 2007 | 284 | 0.070 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2006 | 26 | 0.070 |
Why?
|
| Mutation | 1 | 2011 | 1213 | 0.070 |
Why?
|
| Hematopoiesis | 1 | 2006 | 108 | 0.070 |
Why?
|
| Poly Adenosine Diphosphate Ribose | 1 | 2005 | 4 | 0.070 |
Why?
|
| Aminopeptidases | 1 | 2005 | 6 | 0.070 |
Why?
|
| Intestines | 1 | 2006 | 114 | 0.070 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2005 | 112 | 0.060 |
Why?
|
| Cetrimonium Compounds | 1 | 2005 | 4 | 0.060 |
Why?
|
| Citric Acid | 1 | 2005 | 16 | 0.060 |
Why?
|
| Young Adult | 1 | 2016 | 5710 | 0.060 |
Why?
|
| Spectrophotometry | 1 | 2005 | 54 | 0.060 |
Why?
|
| Tetrazolium Salts | 1 | 2005 | 36 | 0.060 |
Why?
|
| K562 Cells | 1 | 2005 | 44 | 0.060 |
Why?
|
| Biotin | 1 | 2005 | 28 | 0.060 |
Why?
|
| Intestinal Mucosa | 1 | 2006 | 219 | 0.060 |
Why?
|
| Mutagens | 1 | 2005 | 18 | 0.060 |
Why?
|
| Genetic Engineering | 1 | 2005 | 41 | 0.060 |
Why?
|
| Microscopy, Electron | 1 | 2005 | 351 | 0.060 |
Why?
|
| Purine Nucleosides | 1 | 2004 | 3 | 0.060 |
Why?
|
| Female | 6 | 2019 | 38021 | 0.060 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2004 | 7 | 0.060 |
Why?
|
| Thiazoles | 1 | 2005 | 95 | 0.060 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2005 | 123 | 0.060 |
Why?
|
| Models, Chemical | 1 | 2005 | 155 | 0.060 |
Why?
|
| Drug Synergism | 2 | 2016 | 260 | 0.060 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2005 | 172 | 0.060 |
Why?
|
| Gene Deletion | 1 | 2004 | 235 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2017 | 231 | 0.050 |
Why?
|
| Rats | 2 | 2022 | 5300 | 0.050 |
Why?
|
| ADP-Ribosylation | 1 | 2022 | 1 | 0.050 |
Why?
|
| Serine | 1 | 2022 | 99 | 0.050 |
Why?
|
| Nanoparticles | 1 | 2005 | 254 | 0.050 |
Why?
|
| Tyrosine | 1 | 2022 | 196 | 0.050 |
Why?
|
| Trastuzumab | 1 | 2020 | 17 | 0.050 |
Why?
|
| Drug Substitution | 1 | 2020 | 19 | 0.050 |
Why?
|
| Filgrastim | 1 | 2020 | 22 | 0.050 |
Why?
|
| Japan | 1 | 2020 | 68 | 0.050 |
Why?
|
| Bevacizumab | 1 | 2020 | 34 | 0.050 |
Why?
|
| Policy Making | 1 | 2020 | 51 | 0.050 |
Why?
|
| Adult | 2 | 2016 | 21379 | 0.050 |
Why?
|
| Rituximab | 1 | 2020 | 61 | 0.050 |
Why?
|
| Europe | 1 | 2020 | 196 | 0.050 |
Why?
|
| Erythropoietin | 1 | 2020 | 96 | 0.050 |
Why?
|
| Protein Domains | 1 | 2020 | 74 | 0.040 |
Why?
|
| AIDS Dementia Complex | 1 | 2019 | 20 | 0.040 |
Why?
|
| NADPH Oxidase 2 | 1 | 2019 | 16 | 0.040 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 17 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2020 | 149 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 2014 | 1446 | 0.040 |
Why?
|
| Organic Chemicals | 1 | 2019 | 77 | 0.040 |
Why?
|
| Male | 4 | 2019 | 37283 | 0.040 |
Why?
|
| Locomotion | 1 | 2019 | 135 | 0.040 |
Why?
|
| Patient Safety | 1 | 2020 | 202 | 0.040 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2019 | 152 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 2791 | 0.040 |
Why?
|
| Coatomer Protein | 1 | 2017 | 4 | 0.040 |
Why?
|
| Ribosomal Proteins | 1 | 2017 | 18 | 0.040 |
Why?
|
| Gene Library | 1 | 2017 | 68 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2019 | 499 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 2017 | 106 | 0.040 |
Why?
|
| Anxiety | 1 | 2019 | 422 | 0.030 |
Why?
|
| Nicotine | 1 | 2019 | 350 | 0.030 |
Why?
|
| RNA Interference | 1 | 2017 | 266 | 0.030 |
Why?
|
| Alkaloids | 1 | 2016 | 40 | 0.030 |
Why?
|
| Flap Endonucleases | 1 | 2014 | 1 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2014 | 63 | 0.030 |
Why?
|
| Hydrogen Bonding | 1 | 2014 | 66 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2019 | 2083 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2014 | 69 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2020 | 2004 | 0.030 |
Why?
|
| TCF Transcription Factors | 1 | 2012 | 5 | 0.030 |
Why?
|
| Comet Assay | 1 | 2012 | 11 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2012 | 30 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2012 | 37 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2012 | 57 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2012 | 64 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2014 | 1082 | 0.030 |
Why?
|
| beta Catenin | 1 | 2012 | 73 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 2550 | 0.030 |
Why?
|
| DNA, Superhelical | 1 | 2011 | 8 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2011 | 39 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2011 | 111 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2012 | 237 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2011 | 97 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2012 | 852 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2012 | 562 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 614 | 0.020 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2010 | 32 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 447 | 0.020 |
Why?
|
| Surface-Active Agents | 1 | 2010 | 57 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2011 | 432 | 0.020 |
Why?
|
| Crossing Over, Genetic | 1 | 2008 | 1 | 0.020 |
Why?
|
| Gene Conversion | 1 | 2008 | 4 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2020 | 7028 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 2008 | 67 | 0.020 |
Why?
|
| Cell Movement | 1 | 2011 | 630 | 0.020 |
Why?
|
| Elasticity | 1 | 2008 | 103 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2008 | 127 | 0.020 |
Why?
|
| United States | 1 | 2020 | 7338 | 0.020 |
Why?
|
| Polymers | 1 | 2010 | 244 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 756 | 0.020 |
Why?
|
| Base Sequence | 1 | 2008 | 1015 | 0.020 |
Why?
|
| Genes, APC | 1 | 2006 | 15 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2006 | 53 | 0.020 |
Why?
|
| Testis | 1 | 2006 | 37 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2006 | 43 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2006 | 166 | 0.020 |
Why?
|
| Ovary | 1 | 2006 | 99 | 0.020 |
Why?
|
| Molecular Conformation | 1 | 2005 | 128 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2006 | 228 | 0.020 |
Why?
|
| Models, Animal | 1 | 2006 | 252 | 0.020 |
Why?
|
| Hypoxanthine | 1 | 2004 | 8 | 0.020 |
Why?
|
| Xanthine | 1 | 2004 | 14 | 0.020 |
Why?
|
| Cytosine | 1 | 2004 | 12 | 0.020 |
Why?
|
| Oligonucleotides | 1 | 2004 | 34 | 0.020 |
Why?
|
| DNA, Single-Stranded | 1 | 2004 | 41 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2004 | 95 | 0.020 |
Why?
|
| Thymus Gland | 1 | 2004 | 97 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2004 | 204 | 0.010 |
Why?
|
| Binding Sites | 1 | 2005 | 631 | 0.010 |
Why?
|
| Kinetics | 1 | 2005 | 1047 | 0.010 |
Why?
|
| Spleen | 1 | 2004 | 301 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2004 | 381 | 0.010 |
Why?
|
| Swine | 1 | 2004 | 672 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2005 | 706 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2004 | 1692 | 0.010 |
Why?
|